Remember
 
 
At SpeculatingStocks You Can Discover Stocks, Post Anonymously, and React to Posts. Login is Optional.
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.
     
 

July 2, 2008

SpeculatingStocks.com Stock Pick: Maxygen, Inc. (MAXY)

Stock Price: $4.48


Maxygen, Inc. is a biotechnology company that engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States.

MAXY was a huge gainer today, up $0.97 to $4.48, but we don't believe it has yet seen the serious money it deserves from investors. The company announced that Bayer will pay up to $120 million for Maxygen's hemophilia program.

MAXY will receive a $90 million payment up front. Bayer is very high on MAXY's next-generation recombinant Factor VIIa protein for treatment of hemophilia patients.

MAXY may have lost a major asset, but they received a huge chunk of cash that they can use to further their other drug candidates and do further research & development.

MAXY is now trading at a market cap of only around $165.96 million. As of the company's latest quarter, there was $133.58 million in cash, cash equivalents and short-term investments on the balance sheet. Now, add $90 million to this cash balance and you have over $223 million in cash, cash equivalents and short-term investments.

Also, consider MAXY has no debt on their balance sheet and only $10.22 million in total liabilities. The company has also proven that they can sell a drug candidate even before FDA trials for a huge amount of cash. MAXY has a ton of momentum right now, internally and with their stock.

We believe we could see MAXY trading at much higher levels once more investors research it.

 
     
Untitled Document